Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12788312 | 0.90 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL12788663 | 0.88 | ALDH1A1 (0.48) | KDM4EALDH1A1HSD17B10SMN1; SMN2POLB | |
| SCHEMBL12788398 | 0.85 | LMNA (0.45) | KDM4EALDH1A1HSD17B10POLBCYP1A2 | |
| SCHEMBL12846928 | 0.85 | KDM4E (0.41) | KDM4EALDH1A1HSD17B10SMN1; SMN2POLB | |
| SCHEMBL12788750 | 0.85 | CTSD (0.41) | KDM4EALDH1A1HSD17B10SMN1; SMN2POLB | |
| SCHEMBL12788497 | 0.83 | SMN1; SMN2 (0.51) | KDM4EALDH1A1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL12788384 | 0.83 | ALDH1A1 (0.46) | KDM4EALDH1A1HSD17B10POLBCYP1A2 | |
| SCHEMBL12788540 | 0.82 | KMT2A (0.43) | KDM4EALDH1A1POLBCYP1A2LMNA | |
| SCHEMBL12788560 | 0.82 | CTSD (0.45) | KDM4EALDH1A1SMN1; SMN2CYP1A2LMNA | |
| SCHEMBL12788734 | 0.81 | ALDH1A1 (0.39) | KDM4EALDH1A1HSD17B10SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297117-B1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR39, GPR65 | KDM4E 3477/4885ALDH1A1 833/4885HPGD 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.